. The first glimpse of a new era for DNAtargeted therapeutics came through the realization that telomeres can form fourstranded DNA structures that are termed G-quadruplexes [3] [4] [5] 
. Telomeres are DNA sequences that comprise large numbers of simple guanine-rich tandem repeats at the ends of eukaryotic chromosomes, which protect against degradation and genomic instability. Telomerase plays a major part in maintaining cellular immortalization by catalysing telomere extension, and the recognition in the mid-1990s that it was selectively expressed in the majority of human cancers stimulated interest in inhibiting its activity as an anticancer strategy. One approach focused on targeting telomeric sequences that could potentially form G-quadruplexes 6 
.
As a result of research on telomeric G-quadruplexes and the cellular consequences of targeting them with small molecules that stabilize these structures (reviewed in REF. 7 ), their biological and therapeutic significance is well appreciated and continues to be an active field for drug discovery (BOX 2) . Interest in the more general therapeutic significance of G-quadruplexes has expanded during the past decade to include G-quadruplexes in gene promoters as targets, which are the focus of this article.
This interest was sparked by a publication showing that transcriptional repression of the MYC proto-oncogene (herein, MYC refers to c-MYC), which is overexpressed in up to 80% of solid tumours, could be achieved by targeting a putative G-quadruplex in the nuclease hypersensitive element (NHE) in the promoter region of MYC with a small molecule 8 . Further creddence has been lent to the strategy of targeting this class of nucleic acid structures by the more recent identification 9 and small-molecule targeting 10 of an RNA G-quadruplex in the 5′-untranslated region (UTR) of the small GTPase NRAS, and the identification of tight clusters of putative G-quadruplex-forming sequences immediately upstream and downstream of the transcription start site in proliferationassociated genes through bioinformatics studies (see below). Notably, G-quadruplexes are found in the gene promoters of a wide range of genes that are important in cell signalling, which have representatives from the six hallmarks of cancer 11 . As well as transcription factors such as MYC, which is an undruggable target at the protein level owing to its short half-life and unstructured nature 12 , other targets of particular interest include the small GTPase KRAS and the receptor tyrosine kinase KIT, which is a clinically validated drug target for treating gastrointestinal stromal tumours 13 . Consequently, from a drugdevelopment perspective, if robust strategies for therapeutically targeting gene promoter G-quadruplex structures could be established, their potential might be broad, perhaps even analogous to targeting current major drug target families, such as protein kinases. Moreover, the major advantage of targeting G-quadruplexes, compared with previously targeted families of DNA structures, is that they are discrete folded globular DNA structures, and thus small molecules could be designed to selectively recognize and stabilize these structures, which is analogous to drug targeting of folded protein molecules. Indeed, a first-in-class G-quadruplexinteractive compound, quarfloxin, progressed to Phase II clinical trials for cancer (discussed later), providing proof of principle for the potential therapeutic viability of targeting these structures. However, the compound was withdrawn from further trials owing to problems with bioavailability.
In this article, we first describe the evidence for the existence of G-quadruplexes in eukaryotic promoter regions, highlighting genes for which the presence of G-quadruplexes could have particular therapeutic potential. We then discuss progress in the discovery of small-molecule ligands that target these G-quadruplexes, highlighting the challenges for drug development and how they might be addressed. Structure of promoter G-quadruplexes Key structural characteristics of gene promoter G-quadruplexes. The basic elements of a G-quadruplex structure are shown in BOX 1. In principle, G-quadruplexes can be formed from four separate DNA strands (tetramolecular), two separate DNA strands (bimolecular), or a single DNA strand (unimolecular or intramolecular). Gene promoter sequences containing a continuous stretch of a G-quadruplex sequence with four or more G-tracts will normally fold into an intramolecular G-quadruplex, and all studies to date on such sequences show this type of arrangement 14 . However, other possibilities, including bimolecular G-quadruplexes, are also evident in gene promoter regions 15 , and it is likely that other arrangements could exist. Indeed, many putative gene promoter G-quadruplex sequences contain more than four G-tracts, which suggests that they can form more than one discrete arrangement and that such arrangements may be in dynamic equilibrium with each other 16 . Only a few detailed structures of gene promoter quadruplexes have been reported to date
, and all are from nuclear magnetic resonance (NMR) studies [17] [18] [19] [20] [21] [22] [23] , which contrasts with the success of crystallographic analyses on telomeric G-quadruplexes. Both NMR and crystallographic techniques require overcoming problems of conformational heterogeneity. It is usually necessary to screen several sequences in which ambiguity -resulting from G-tracts that contain differing numbers of guanines -is eliminated, and varying 5′ and 3′ ends are tried until a stable single conformer is found. Circular dichroism and chemical footprinting are useful techniques that can provide information on overall topology, although conformational heterogeneity can complicate their interpretation 24 . Using these less precise and less definite techniques, the folding patterns of several promoter G-quadruplexes have been proposed. These include folding patterns for the genes encoding MYC 25 , B cell lymphoma 2 (BCL-2) 26 , vascular endothelial growth factor (VEGF) 27 , hypoxia-inducible factor 1α (HIF1α) 28 , the transcription factor MYB 29 , platelet-derived growth factor α polypeptide (PDGFA) 30 , PDGF receptor β polypeptide (PDGFRβ) 31 , KRAS [32] [33] [34] , retinoblastoma protein 1 (RB1) 35, 36 and human telomerase reverse transcriptase (TERT) 37 . Although MYB was only discovered to have a G-quadruplex sequence downstream of the transcription start site in 2008, the unusual heptad-tetrad structure of the MYB G-quadruplex was originally solved by NMR in 2001 (REF. 20) and was the first naturally occurring parallel G-quadruplex to be characterized
Unlike telomeric G-quadruplexes, which can be formed from the single-stranded DNA template at the 3′ end of human telomeres, G-quadruplexes in gene promoter regions are constrained by the duplex nature of genomic DNA. Thus, an important question is how secondary structures such as G-quadruplexes can energetically compete with duplex DNA, particularly in view of the GC-rich nature of the putative sequences that form these structures, as at first sight they seem to have higher melting temperatures than AT-rich regions. Although conditions that mimic molecular crowding owing to high concentrations of macromolecules in the nucleus may stabilize these structures once they are formed, other dynamic forces that are derived from negative superhelicity generated by transcription are likely to be involved in the evolution of these structures from duplex DNA
Evidence for G-quadruplexes in vivo.
Most studies on G-quadruplexes have been carried out in ex vivo systems, although the occurrence of these structures in telomeres has been unequivocally demonstrated in ciliates 38 . In the absence of direct evidence for G-quadruplexes in promoter regions of genes, the identification of proteins or enzymes that have important roles in facilitating either the formation of these structures or their unfolding (once they are formed) can provide strong circumstantial evidence of their presence in cells. This evidence would be strengthened if specificity could be demonstrated and the proteins are found to have the expected biological consequences in cells -for example, in silencing or activating gene transcription.
The best characterized system in this regard is the MYC G-quadruplex, in which both types of G-quadruplex-modulating proteins have been identified and their roles in cells have been demonstrated, as a consequence of their interactions with the MYC G-quadruplex 39, 40 (FIG. 1A) . The first potential MYC transcriptional activation protein that was not a classical transcription factor was identified in 1993 (REF. 41 ). This protein, NM23H2, which belongs to the Box 1 | The key structural components of a G-quadruplex Simple G-quadruplex structures are built from the following components: a core of two or more π-π stacked G-quartets (a very stable planar arrangement of four guanine bases that are hydrogen-bonded via Hoogsteen pairings); essential alkali metal ions (Na + or K + ) that coordinate to O6 atoms of the guanine bases and are organized in a linear array running through the centre of the core of G-quartets; and intervening variable-length sequences.
The intervening variable-length sequences hold together the G-quartets and form loops that are arranged on the exterior of the core. The loops are the major elements that define structural variability in G-quadruplexes, and are analogous to side-chains in amino acids. Even one short-length loop (<3 nucleotides) generally results in a G-quadruplex topology with at least two of the four backbones in a parallel orientation, and often with all four parallel to each other; this appears to be the dominant fold in most gene promoter G-quadruplexes examined to date.
The variability in loop sequences results in highly variable (and sometimes flexible) cavities on the exterior of G-quadruplexes that can form part of ligand binding sites. The example shown in the figure is for the dominant G-quadruplex structure that is found in the B cell lymphoma 2 (BCL-2) promoter 26, 117 , in which the loop lengths are 3, 7 and 1 nucleotides. In this case the small loop forms a parallel orientation and the two larger loops form antiparallel orientations. The stability of G-quadruplexes arises from the interplay between these various components. Thus, although other bases -such as thymine -can also form quartets, they are all significantly less stable than a G-quartet and, crucially, they are unable to effectively form the characteristic alkali metal ion channels. non-metastasis 23 (NM23) family of proteins, was shown -via a reporter assay -to bind to the nuclease hypersensitive element III 1 (NHE III 1 ) sequence of the MYC promoter to stimulate promoter activity 41, 42 . Before NM23H2 was identified as a transcription factor, it was known as nucleoside diphosphate (NDP) kinase, a housekeeping enzyme that was important for the maintenance of nucleotide pools 43 . Mutational studies have shown that these two activities of the protein are in distinct domains 44 . In 1995, NM23H2 was shown to be a footprint in the NHE III 1 of the translocated MYC allele in Burkitt's lymphoma cells 45 . More recently, it has been shown that NM23H2 binds to the two singlestranded elements of the NHE III 1 sequence and that this binding affinity is lost following mutation of Arg88 to Ala88 in the active site, which binds to the phosphate of a key nucleotide in the 47-mer deoxynucleotide oligomer substrate 39 . Significantly, NM23H2 did not bind to the MYC G-quadruplex, and in experiments in which small G-quadruplexinteractive molecules, such as TMPyP4, or ionic conditions, such as potassium chloride, stabilized the G-quadruplex (see later), NM23H2 was prevented from binding to this single-stranded template, thus suggesting that this enzyme could facilitate unwinding of the G-quadruplex and the i-motif (which is formed from the complementary C-rich strand) 46 . Using chromatin immunoprecipitation (ChIP) assays with an NM23H2-specific antibody, Chowdhury and colleagues 47 have shown that this protein binds to the MYC promoter. They also conclude, on the basis of luciferase assays, that NM23H2 induces MYC transcription and unfolds the G-quadruplex. This is proposed to occur in a stepwise manner in which the hexameric protein successively captures the single-stranded GC-rich strands in a weak binding complex that can be transferred to other duplex-binding proteins (for example, transcription factor Sp1) or single-stranded DNA-binding proteins (for example, CCHC-type zinc finger, cellular nucleic acid binding protein (CNBP) and heterogeneous nuclear ribonucleoprotein K (HNRNPK)) to activate transcription (FIG. 1) . Although HNRNPK is a single-stranded DNA-binding protein, a recent publication has suggested that CNBP may also bind to the MYC G-quadruplex 48 . In line with this role, cellular levels of NM23H2 correlate with MYC levels in colon cancer cell lines, and small interfering RNA (siRNA) knockdown experiments of NM23H2 demonstrate inhibition of MYC levels in these cell lines 39 .
The inhibition of MYC transcription by the small-molecule ligand TMPyP4 (see discussion below) can also be rationalized by the stabilization of the MYC G-quadruplex and prevention of NM23H2-induced unwinding of the G-quadruplex (FIG. 1B) .
Affinity chromatography has also been used to identify nuclear proteins that bind to the MYC G-quadruplex 40 . Nucleolin was identified as the major protein that binds to the MYC G-quadruplex, together with a number of other nucleolin-associated proteins. Importantly, nucleolin bound with higher affinity to the MYC G-quadruplex than its previously described RNA substrate (nucleolin recognition element) and had a higher selectivity for parallel G-quadruplexes over other naturally occurring G-quadruplexes that have different folded structures 40 . Nucleolin not only stabilized the MYC G-quadruplex but also facilitated its formation from the singlestranded oligomer. Cellular experiments demonstrated that nucleolin repressed MYC transcription and significantly prevented Sp1-induced MYC transcription. Last, ChIP analysis showed that nucleolin bound to the NHE III 1 in the MYC promoter in cells. As nucleolin only binds to the G-quadruplex and not to other forms of DNA found in the NHE III 1 , and ChIP analysis shows that nucleolin binds to this element in cells, this is the best evidence to date that the MYC G-quadruplex exists in a cellular context. The relationship among Sp1, CNBP, HNRNPK, NM23H2, nucleolin, the G-quadruplex/i-motif and MYC transcription is shown in FIG. 1A , which represents a general model for how secondary DNA structures can control transcription when the G-quadruplex/i-motif is the silencer element.
More recently, Sun et al. 49 provided strong evidence for the formation of a G-quadruplex in the promoter region of the human VEGF gene. This G-quadruplex is closely related to the one found in the MYC promoter, and consists of a parallel G-quadruplex that has loop ratios of 1/4/1. Parallel footprinting experiments with dimethyl sulphate (DMS) were carried out at three different levels on the same sequence: a single-stranded template, a duplex contained in a supercoiled plasmid and in
Box 2 | Targeting telomeric G-quadruplexes in cancer
The telomerase enzyme complex, which is selectively expressed in most tumours, maintains telomere homeostasis and hence has a key role in cellular immortalization and transformation 118 . Telomerase maintains telomere length by virtue of its reverse transcriptase activity and, in humans, it catalyses the synthesis of TTAGGG telomeric DNA repeats. The concept that inhibition of telomerase may be an effective anticancer strategy has been supported by extensive preclinical data on the oligonucleotide GRN163L, which inhibits the catalytic function of telomerase by targeting its template domain (for example, see REF. 119) .
A distinct approach for telomerase inhibition via telomeric G-quadruplexes 6 showed that appropriate small molecules can induce the 3′ ends of human telomeric DNA (with the terminal 150-200 nucleotides being single-stranded) to fold up into G-quadruplex-ligand structures, which render the ends inaccessible to telomerase template recognition and hence to telomere repeat addition. Subsequent work in the telomere field in the past decade has focused on the structural characterization of the human telomeric G-quadruplex structures [120] [121] [122] [123] 124 , evidence for the occurrence of these structures in ciliates 38 and the cellular consequences of targeting these structures (reviewed in REF. 7 ). As a result of this body of work, the role of ligand-stabilized telomeric G-quadruplexes is well accepted by those involved in both chemical and biological research.
Several hundreds of small molecules that interact with telomeric G-quadruplexes have now been described in the literature. Their binding in vitro to human telomeric G-quadruplexes has been extensively explored 125, 126 , although cellular and in vivo data are only available for a small number of compounds 7 , in particular the cyclic polyoxazole natural product telomestatin 127 and the synthetic acridine compounds BRACO19 (REFS 128, 129) and RHPS4 (REFS 130, 131) . There is compelling evidence that these compounds act not only by inhibiting the catalytic function of telomerase but also by uncapping telomerase from the 3′ ends of telomeres. They also induce selective and potentially therapeutically important rapid DNA damage responses in cancer cells 132 involving several pathways, notably the activation of poly(ADP-ribose) polymerase (PARP) 133 and ataxia telangiectasia mutated (ATM) signalling 134, 135 . Evidence of antitumour activity in various xenograft models has been reported for telomestatin, BRACO19 and RHSP4, although no telomere-targeted G-quadruplex ligand has as yet progressed to clinical evaluation, probably because of the undrug-like characteristics of these and many other existing compounds. There have, however, been reports 132, 136 of non-polycyclic compounds with drug-like features and promising in vitro profiles.
cells. At the single-stranded and duplex DNA levels, DMS footprinting was used 49 . Significantly, the DMS-protected G-tracts were almost the same at all three levels. Furthermore, deoxyribonuclease I footprinting and ChIP analysis have demonstrated that nucleolin is bound to the G-quadruplexforming region in plasmids and in cells.
Genome-wide analysis of putative G-quadruplex-forming regions in gene promoters. The advancement in our understanding of the biophysical principles that link G-quadruplex formation in vitro with oligonucleotide sequences has provided a rational basis for constructing algorithms that predict sequences that are likely to fold into intramolecular G-quadruplexes [50] [51] [52] . Various G-quadruplex search algorithms have been published, ranging from those that use more explicit definitions of nucleotide arrangements (for example, GGG 3+ N 1-7 GGG 3+ N 1-7 GGG 3+ N 1-7 GGG 3+ N 1-7 ) 52, 53 to methods that identify windows of sequences that comprise sets of guanine clusters (for example, GGGN x GGGN y GGGN z GGG, in which 12 + x + y + z < size of window) 54, 55 . All such algorithms are imperfect and will generate some false positives and false negatives, but they have proven to be valuable for the elucidation of patterns of G-quadruplex motifs with respect to genome structure and function. A rigorous test for a predicted individual G-quadruplex motif will require biophysical analysis of an oligonucleotide of the corresponding sequence.
Early computational surveys of the human genome have revealed that G-quadruplex sequence motifs are prevalent in the genome, with a similar estimate of ~370,000 motifs observed in two independent studies using distinct algorithms 50, 52 . The initial genome-wide surveys have been followed up by computational studies that have concentrated on exploring the incidence of G-quadruplex motifs in regions of genes that are normally associated with function. A functionally important part of the genome that is under particular investigation is the sequence space that is proximal to the transcription start sites of genes, which are associated with core promoter elements. G-quadruplex motifs are enriched in regions that are proximal to the transcription start sites of protein-coding genes in genomes, including prokaryotic 56 , human 53, 56, 57 , chimpanzee 57 , rat 57 , mouse 57 and yeast 54 genomes. For example, FIG. 2 shows a probability density plot that exhibits a strong positional bias for G-quadruplex sequences, with a peak density of ~50 nucleotides upstream 53, 58 , which is analogous to the positional bias that is found for known transcription regulatory sites 59 (FIG. 2) . Several helpful databases have now been compiled to facilitate the study of G-quadruplexes that are potentially involved in the regulation of genes 60, 61 . A similar positional bias has been observed in the upstream promoter regions of mouse, rat 57 and yeast genomes 54 and in the upstream regions of genes in the Escherichia coli genome 56 . A positional bias for G-quadruplexes has been observed in the first intron, which is downstream of gene promoters 62 . Several genomic computational studies have also revealed that G-quadruplex sequence motifs tend to be present outside nucleosome-bound regions in the genomes of Saccharomyces cerevisiae 63 , Caenorhabditis elegans and humans 64 . These cross-species observations might be explained in terms of a general regulatory role of these G-quadruplex sequence elements. A computational comparison has revealed that predicted transcription
Box 3 | NMR structures of gene promoter G-quadruplexes
Only a few detailed structures of gene promoter G-quadruplexes have been reported to date, and all are from nuclear magnetic resonance studies [17] [18] [19] [20] [21] [22] [23] , which contrasts with the relative success of crystallographic analyses on telomeric quadruplexes. Below are the sequences and structures of selected gene promoter G-quadruplexes.
BCL-2, B cell lymphoma 2; PDB, Protein Data Bank. Box 4 | Negative superhelicity in G-quadruplex formation: MYC as an example
Telomeric G-quadruplexes are readily available in a single-stranded DNA template, whereas G-quadruplexes in gene promoter elements are constrained by the duplex nature of genomic DNA. An important question, therefore, is how secondary structures such as G-quadruplexes and i-motifs (which are formed from the complementary C-rich strand from hemiprotonated cytosine + -cytosine base pairs (bp)) can energetically compete with duplex DNA, particularly in view of the GC-rich nature of the putative sequences that form these structures, as they seem to have higher melting temperatures than AT-rich regions.
Conditions that mimic molecular crowding owing to high concentrations of macromolecules in the nucleus may stabilize these structures once they are formed; however, other dynamic forces derived from negative superhelicity generated by transcription are also highly likely to be involved in the evolution of these structures from duplex DNA. The energetics of duplex to G-quadruplex/i-motif structures has been discussed in more quantitative terms by Lane et al. 137 in terms of kinetic versus thermodynamic control. In addition to negative superhelicity and molecular crowding conditions, a key factor is stabilization of the resulting secondary DNA structures by proteins and ligands.
As a prerequisite to its formation from duplex DNA, the region containing the G-quadruplex/i-motif must first be nucleosome free. The observation that these putative G-quadruplex/i-motif-forming regions are clustered in close proximity upstream to the transcription start site, and that these regions are often associated with nuclease sensitive sites provides indirect support for the premise that secondary DNA structures such as G-quadruplexes can be formed from duplex DNA by transcriptionally induced negative superhelicity. This is because the superhelical torque is highest in close proximity to the transcription start site and is likely to result in the melting of duplex DNA, which is detected by nucleases.
The promoter configuration for the MYC promoter is shown in the figure, part a, and shown in the inset is the 33-mer sequence of the purine-rich strand upstream of the P 1 promoter 68 . Levens and colleagues 138 have elegantly demonstrated that negative superhelicity is generated from the forward movement of the DNA as it screws its way through the multiprotein transcriptional complex that is associated with RNA polymerase, and this superhelicity can be propagated at large distances from the transcription start site in the MYC promoter, even in the presence of topoisomerases. To mimic this situation in cells, the wild-type G-quadruplex-forming sequence in the MYC promoter and a mutant sequence containing a single guanine mutation in the centre of a critical run of three guanines required for G-quadruplex stability were cloned into a plasmid that inherently contained negative supercoiling 46 . Footprinting experiments using chemical reagents (for example, DMS (dimethyl sulphate), KMnO 4 and Br 2 ) and enzymatic footprinting (for example, S1 nuclease and deoxyribonuclease I) demonstrated that both the wild-type sequence and a negatively supercoiled plasmid were necessary to facilitate the formation of the MYC G-quadruplex 46 . Significantly, chemical footprinting signatures for both the G-quadruplex and the i-motif were present under negative supercoiling conditions in the wild-type sequence; however, these were offset such that the G-quadruplex was constrained in the 5′ end of the G-rich strand and the i-motif was confined to the 5′ end of the C-rich strand, producing overhangs of 5 and 14 bp at the end of the nuclease hypersensitive element III 1 (NHE III 1 ) (see the figure, part b) . In previous studies that used circular dichroism, DMS footprinting and nuclear magnetic resonance techniques in a single-stranded DNA template, only the five 5′ runs of three or more contiguous guanines were used 8, 17, 22, 23, 25 . Under negative supercoiling conditions and in the context of duplex DNA, guanine runs 1-4 are used, and the i-motif uses a sixth run at the 5′ end of the cytosine tract, in contrast to the results with single-stranded DNA GC-rich templates 139 , which were not anticipated. The remaining issue as to why this GC-rich region is the favoured sequence for unwinding and subsequent formation of the G-quadruplex/ i-motif -rather than other adjacent AT-rich sequences, which would seem to have a lower energy barrier for formation of the intermediate single-stranded regions -can be addressed from two different perspectives. First, where there are successive runs of guanines that can form 'slipped mismatched structures', this may provide stable intermediates that can lead to these secondary structures 140 . Consequently, once formed, the G-quadruplexes can be trapped out by proteins that specifically bind to and stabilize these structures (see main text). Second, under negative supercoiling conditions, the i-motif can form even in the absence of the G-quadruplex 46 , and once one of these structures is formed, it is likely to favour the opposite strand to form the complementary structure. Using single-molecule fluorescence studies, the promotion of non-duplex structure in the KIT promoter DNA by a G-quadruplex motif has been demonstrated (see main text) 87 .
factor binding sites are either proximal to or overlap with G-quadruplex motifs in upstream elements 62, 65 , which would be consistent with a molecular mechanism whereby G-quadruplex motifs and structure formation modulate transcription factor binding events.
These data demonstrate that, theoretically, G-quadruplex sequences in the human genome are statistically overrepresented, but an important and as yet unanswered question is whether all of the sequence motifs that have been identified translate into the formation of stable G-quadruplex structures in a cellular context. Moreover, depending on the environment in which the sequence is located, different G-quadruplex structures can form. There have been a number of studies describing genome-wide experimental data that support a linkage between the formation of G-quadruplex structures in cells and gene expression. One study grouped genes according to the number of G-quadruplex motifs that are proximal to transcription start site regions and showed that the mean expression levels of genes that comprise downstream G-quadruplexes (transcription start site + 500 base pair region) were higher than that of genes that lack G-quadruplexes in this region 66 . Furthermore, the mean expression level increased with the number of downstream G-quadruplex motifs. Other genome-wide expression studies have been reported, in which either a small molecule 54, 56 or protein 67 ligand that is specific for G-quadruplex DNA has been shown to perturb the expression of genes with a statistically significant bias toward genes with one or more G-quadruplex motifs proximal to the transcription start site.
Interestingly, in one genome-wide survey the prediction of G-quadruplex motifs correlated with the function of human genes -showing, for example, an overrepresentation in proto-oncogenes and an apparent depletion in tumour suppressor genes 55 . This observation suggests that there may have been evolutionary selection for G-quadruplex structures based on function. It also suggests that G-quadruplexes, which are associated with proto-oncogenes, are a therapeutically relevant class of potential drug targets.
The following section considers selected examples of cancer-related genes for which there is substantial evidence for the existence of G-quadruplexes in gene promoter regions and strong support for the therapeutic potential of targeting the activity of the gene product. 
Promoter G-quadruplexes as targets
In the following section, we discuss in more detail the therapeutic potential of targeting G-quadruplexes in MYC, KIT and KRAS to modulate the function of these genes. These genes were selected from the more comprehensive list detailed earlier, which also included BCL-2, VEGF, HIF1A, MYB, PDGFA, PDGFRB, RB1 and TERT, because of their more in-depth evaluation; however, this is not meant to imply that the other genes are less attractive as drug targets.
MYC.
Deregulation of the transcription factor MYC is almost always as a consequence of gene amplification, translocations, altered ploidy or enhanced transcription owing to upstream signalling abnormalities 68, 69 . Up to 80% of all solid tumours overexpress MYC, including gastrointestinal, ovarian and breast cancer tumours 11, [70] [71] [72] [73] [74] , as do many nonHodgkin's lymphoma tumours 11 , and so it has attracted considerable interest as a potential therapeutic target. Importantly, however, MYC expression is not always a negative prognostic factor. For example, in oestrogenpositive breast cancer, MYC expression is crucial for hormone therapy. Consequently, the genetic and therapeutic context of treatment must be considered before anti-MYC therapies are designed 75 . Finally, it is important to appreciate that because the control of MYC expression is extremely complex 74 , there are other pathways and mechanisms that may be used as an alternative to those involving the NHE III 1 . A more complete description of the therapeutic implications of targeting MYC via the G-quadruplex is given in recent reviews 11, 76 . As mentioned above and described in BOX 4 and FIG. 1 , the G-quadruplex-forming region in the MYC promoter is the most studied example of such a region. The 33-nucleotide sequence in NHE III 1 (TGGGG AGGGTGGGGAGGGTGGGGAAGGTGG GGA) contains six G-tracts of unequal length
, which unsurprisingly form a complex mixture of G-quadruplex structures in solution. Two separate NMR studies on the four central guanine tracts have shown that it has an intramolecular parallel topology, with one two-nucleotide and two single-nucleotide propeller loops, whereas another sequence containing the four central guanine tracts similarly forms a parallel quadruplex with a GGA triad stacked on one end 17, 23, 77 . It was first demonstrated in 2002 that the G-quadruplex in the MYC promoter element was a silencer element and that stabilization with the G-quadruplex interactive molecule TMPyP4 (FIG. 3) led to inhibition of MYC expression 8 . The ligand-or drug-mediated effect on MYC transcription by stabilization of the G-quadruplex has been independently demonstrated in subsequent work with quindolines and actinomycin D 78, 79 . In situations in which an isolated G-quadruplex is present in the gene promoter, mutational studies that destabilize the G-quadruplex without preventing transcription factor binding can be used to demonstrate the role of G-quadruplexes in transcriptional activation. Thus, a specific G→T mutation in the MYC promoter that is known to destabilize the G-quadruplex resulted in an increase in transcription, which was partially alleviated by compounds that stabilize the G-quadruplex 8 . Finally, two Burkitt's lymphoma cell lines (CA46 and Ramos) have been used to directly demonstrate the differential effect on MYC gene expression of TMPyP4 and TMPyP2 (a positional isomer of TMPyP4 that is much less effective than TMPyP4 at stabilizing the MYC G-quadruplex). As only the Ramos cell line retains NHE III 1 under constitutive control of the heavy chain immunoglobulin region following translocation, it would be expected that the Ramos cell line would express significantly more MYC than the CA46. Furthermore, TMPyP4 but not TMPyP2 should selectively inhibit MYC expression uniquely in the Ramos cell line, and this is precisely what was observed 8 .
KIT.
The KIT proto-oncogene encodes a receptor tyrosine kinase that, upon activation by its ligand, stimulates cell proliferation, differentiation and survival 80 . Activating mutations or overexpression can result in aberrant function and oncogenic cellular transformation in melanocytes, mast cells, myeloid cells, germ cells and interstitial cells of Cajal lineages. Constitutive activation of KIT is considered to be the primary pathogenic event in gastrointestinal stromal tumours (GIST) 81 and may have an important role in a number of other malignancies in which KIT expression is elevated. Consequently, the KIT protein has become a major molecular target of focus for GIST therapy, as exemplified by the multitargeted kinase inhibitors imatinib (Glivec/Gleevec; Novartis) and, more recently, sunitinib (Sutent; Pfizer) 82 . Figure 2 | Identification of putative G-quadruplex-forming regions in gene promoters using computational analysis. The density plot shows the frequency (that is, the probability) of each nucleo tide upstream (-ve) or downstream (+ve) of the transcription start site being part of a putative G-quadruplex-forming sequence (PQS), based on the Quadparser algorithm 50 . The data has been averaged over all human protein coding genes in the genome. The blue and red plots reflect the presence of a G-quadruplex motif (G-PQS) or the C-rich complement of a G-quadruplex motif (C-PQS), respectively. The downstream data are related to the spliced sequence (that is, exons), and there is clearly some evidence of strand bias, in contrast with the symmetry between the blue and red plots in the upstream sequence. However, the clinical challenges posed by the emergence of drug resistance owing to mutations in the KIT protein suggest that alternative or indeed complementary approaches would be desirable, even with the availability of second-generation KIT inhibitors.
Two G-quadruplex-forming sequences, designated KIT1 (REF. 83 ) and KIT2 (REF. 18 ), lie within a stretch that was previously shown to be part of the core promoter of KIT 84 (FIG. 4a) . They occur between position -87 and -109 base pairs (KIT1) and between -140 and -160 base pairs relative to the transcription start site (KIT2) and flank a validated Sp1 binding site with close proximity 18, 19, 21 (FIG. 4a) . Both sequences have been shown to form stable G-quadruplexes in vitro, and the threedimensional structures have been recently solved for each sequence 19, 21 More recently, Patel and colleagues 85 have shown that KIT2 can also form a dimeric structure. The KIT1 sequence is d(AGGGAGGGCGCTGGGAGGAGGG) with four apparently identical GGG tracts. Contrary to the initial expectation of a simple parallel topology, the core of three stacked G-quartets in the actual NMR structure is not built up from these four tracts alone, but instead involves the G in the CGCT sequence 21 (FIG. 4a) . Only two of the three 3′ end guanines in the final G-tract participate in G-quartets and they do so by being at the end of the long pentanucleotide AGGAG lateral-type loop that turns back into the core of the quadruplex to put these two guanines in proximity. This large loop, which is stabilized by two A·G base pairs, forms the side and floor of a pronounced cleft, which is a potential ligand binding site (see later). Nineteen of the twenty-two nucleotides in the KIT1 structure are conserved, and a search of the human genome database shows that the sequence has a unique occurrence in the human genome, which suggests that the structure itself is unique among gene promoter G-quadruplexes 86 . A more recently determined NMR structure of the KIT2 quadruplex 19 , which was formed from the G21T mutant of the d(CGGGCGGGCGCGAGGGAGGGG) sequence, shows a more conventional parallel topology, although it is structurally more heterogeneous than the KIT1 quadruplex. This heterogeneity is probably largely a consequence of the long flexible loop that is formed by the CGCGA sequence. The KIT2 sequence is similarly of unique occurrence in the human genome and is highly conserved in eukaryotes. A second NMR analysis of this sequence has shown that a distinct KIT2 quadruplex can also be formed by the dimerization of two monomers, which involves a novel parallel-stranded topology 85 . This structure may well have implications for the folding of G-quadruplexes in G-rich strandexchanged recombination regions of the genome, although it has little direct relevance to KIT function.
In the case of KIT2, through a biophysical study using single-molecule Förster resonance energy transfer (FRET) spectroscopy, it has been shown that the G-quadruplexforming potential of the sequence was sufficient to promote non-duplex structure formation within the context of an extended DNA duplex 87 . A 100-base-pair double helical DNA sequence, which was taken Single-molecule analysis of this system demonstrated subpopulations in which the G-quadruplex region adopted either a duplex or a non-duplex structure. The non-duplex structure was absent when the G-quadruplex motif was mutated to prevent G-quadruplex formation. This property suggests that there is a relationship between the DNA sequence and a non-duplex structure, which may have temporal and/or functional relevance to the onset of KIT transcription. Chemical biology studies using small molecules have provided further evidence in support of KIT promoter G-quadruplexes as molecular targets (see later).
KRAS.
Activating mutations in the gene coding for KRAS -which has a role in many signal transduction pathways -are of particular importance to the pathogenesis of pancreatic carcinomas. Although the KRAS protein has been actively pursued as a molecular target for therapeutics, it has proven to be challenging to find drugs that act at the protein level.
Parallel studies on the polypurine and polypyrimidine NHEs of the murine 33 and human 32 KRAS promoters have been carried out, which are the focus of discussion here. Biophysical studies have shown that there are two different G-quadruplex structures that can form within the NHE of the human KRAS promoter 32 . Studies in pancreatic cancer cell lines that overexpress KRAS showed that KRAS mRNA levels were lowered in the presence of TMPyP4 (REF. 32 ). Furthermore, the KRAS DNA G-quadruplex-forming element has been used as an affinity probe to isolate proteins such as 5′-deoxyribose-5-phosphate lyase Ku70, poly(ADP-ribose) polymerase 1 (PARP1) and heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) from nuclear extracts 32 , and in a subsequent study, HNRNPA1 has been shown to unwind G-quadruplex DNA 34 . In a different system, it is noteworthy that PARP1 has been shown to bind tightly to G-quadruplex DNA (K d = 65 nM) and to be enzymatically activated following binding 88 . Recent work on the murine Kras promoter has demonstrated that both PARP1 and the MYC-associated zinc finger can recognize the KRAS promoter quadruplex, which has led to a proposed transcription mechanism involving this zinc finger, PARP1 and the G-quadruplex structure 89 .
Oligonucleotides that mimic one of the G-quadruplexes found in the human KRAS promoter have been shown to compete for protein binding with the G-quadruplexes in the natural promoter, in a pancreatic nuclear extract 90 . In an interesting application of G-quadruplex-forming oligodeoxynucleotides, specific covalently linked polyaromatic stacking units were shown to both stabilize the G-quadruplexes and have a strong antiproliferative effect 90 .
Implications for druggability. Although G-quadruplexes can take numerous conformations, there are common features among the G-quadruplex structures that may be harnessed to develop small molecules that bind to them. For example, a structural feature that is common to all G-quadruplexes -the large planar surface of a terminal G-quartet -has led to the development of many small-molecule families that are based on heteroaromatic systems that complement the G-quartet platform. However, this feature by itself is insufficient for high affinity and unlikely to confer selectivity.
Structural selectivity for a particular G-quadruplex might be achievable in several ways -for example, by restricting access to the G-quartet platform as a consequence of the steric hindrance imposed on them by loops, which will emphasize particular ligand shapes, or via sequence-dependent grooves and loops, which provide binding pockets for ligand side chains. There are as yet few molecular structures for promoter quadruplexes. Those that are currently known (MYC and KIT) are from NMR studies, and they do show considerable structural diversity such that selective small-molecule targeting could be feasible. This diversity is in contrast to the challenges posed in the kinase field by attempts to differentiate between ATP binding sites within a family of kinases. For example, a study by Kumar et al. 91 that used a panel of 242 kinases highlighted the varying degrees of kinase promiscuity of the approved kinase inhibitors pazopanib (Votrient; GlaxoSmithKline), sorafenib (Nexavar; Onyx/Bayer) and sunitinib.
We suggest that the very diversity of G-quadruplex structures could be used to enhance selectivity. In particular, exploitation of the different grooves and loops that are present in G-quadruplex structures has not yet been undertaken in a systematic manner, not least because of the paucity of firm structural information. However, screening of focused libraries of small molecules has resulted in the identification of several high-affinity small molecules for the KIT1 and KIT2 G-quadruplexes (see later). In the case of the KIT1 quadruplex structure, there is a pronounced cleft that may be suitable for ligand binding and highthroughput in silico screening. This cleft is distinct from the more usual G-quadruplex binding sites, and has so far not been found to be present in any other known quadruplex structure (FIG. 4b) . A future goal would be to determine high-resolution crystal structures for promoter quadruplexes, as this will define groove and loop geometries.
Nevertheless, a major challenge is that it is not feasible, at least for the foreseeable future, to screen or design small molecules against the large number of gene promoters and other G-quadruplex structures that are likely to be prevalent in the human genome. One potential solution is to focus on those gene promoter G-quadruplex targets that have unique sequences and possess structural features as well, such as the KIT quadruplexes, and to design specific molecules solely for them. One approach that could offer the potential of achieving the twin objectives of high affinity and specificity is gene targeting with a peptide nucleic acid probe, and this has been shown in vitro to be achievable with these probes 92 . However, if this concept is to be evaluated in cells, there will be significant hurdles to overcome, as short probe sequences may also hybridize to many duplex DNA sequences. Nevertheless, many small molecules are currently available that stabilize G-quadruplexes, and they could perhaps be used as a platform to develop more specific agents. These small molecules, and the most advanced G-quadruplex-interacting molecule developed to date, quarfloxin, are discussed in the next section.
Promoter G-quadruplex-ligand complexes Small-molecule ligands as tools. The therapeutic potential of gene promoter G-quadruplexes has resulted in a rapidly increasing number of studies in which small-molecule ligands have been used to act as G-quadruplex stabilizers, in several instances with cell-based assays. The porphyrin TMPyP4 (FIG. 3) is a G-quadruplextargeting ligand that has been used in a large number of studies, especially those concerned with elucidating the biological role of G-quadruplexes.
Quindoline and berberine (a related plant alkaloid) are classic G-quadruplexbinding agents that comprise planar aromatic chromophores with one or two aminoalkyl side chains 93, 94 . Derivatives of both these agents have been reported to show significant antiproliferative properties and to downregulate MYC expression in several cancer cell lines 79 , as well as effectively binding to MYC in vitro and in PCR stop assays. However, their selectivity for one particular type of G-quadruplex type is modest, as shown by the quindoline derivative SYUIQ-5, which inhibits MYC promoter activity in a cell-free system and in two leukaemia cell lines 95 , and acts as a telomerase inhibitor and inducer of telomere damage (possibly via stabilization of telomeric G-quadruplex DNA) 96 . All of these ligands have significant affinity for duplex DNA, so their mode of action is complex; however, given the dominant role of MYC in many human cancers, their effects on MYC expression are likely to be major factors in their antiproliferative activity.
A recent report on the binding of some platinum complexes to MYC G-quadruplexes, with significant selectivity over duplex DNA, highlights the potential for ligand structural diversity 97 , although the affinity of these compounds to other promoter quadruplexes remains to be explored.
A more selective agent for the MYC G-quadruplex is the telomestatin derivative S2T1-6OTD (FIG. 3) , which has been shown to reduce the expression of MYC and TERT (which codes for the catalytic subunit of telomerase and is transcriptionally regulated by MYC) in childhood medulloblastoma and in atypical teratoid-rhabdoid tumour cells; this results in cell-cycle arrest, and has potent antiproliferative effects 98 . Although S2T1-6OTD causes telomere shortening in these cells, this effect is largely MYC-dependent. Telomestatin (FIG. 3) has been shown to bind to the G-quadruplex in the TERT promoter, and this may mediate at least part of its effect on telomeres 37 . Significantly, this ligand has no detectable effects on the stability of duplex DNA.
Trisubstituted isoalloxazines (FIG. 3) that bind to and stabilize the G-quadruplexes formed by KIT1 and KIT2 have been shown to reduce KIT transcript levels in cells that express KIT 99 . Recent studies with patient-derived GIST882 cells that contain gain-of-function KIT mutations have shown that a naphthalene diimide G-quadruplex ligand (FIG. 3) can arrest cell growth in a dose-dependent fashion 100 . Mechanistic markers showed a suppression of KIT mRNA and KIT protein levels as well as effects on telomerase activity, suggesting a dual-mode of action. Recently, benzo[a]phenoxazines were identified as potentiators of KIT expression. Biophysical data suggest that these particular ligands preferentially bind to the G-quadruplex formed by KIT2 (REF. 101 ).
The studies described in this section are examples of cases in which there is clear biophysical evidence of the associated small-molecule binding to the G-quadruplex DNA target in vitro, in some cases with selectivity for the target in question relative to duplex DNA or indeed other G-quadruplex sequences. Although the effects of such small molecules on specific cellular mechanisms and the associated growth inhibitory effects are promising in terms of their development into potential anticancer therapeutics, a number of future challenges must be addressed to confirm the robustness of the G-quadruplex targeting concept. These challenges include the need to definitively demonstrate that such molecules are interacting with the expected molecular targets in cellular DNA and to explore whether selectivity between various G-quadruplexes is attainable -or indeed required -in cells to achieve the desired selectivity windows for therapeutics. In this respect, the development of quarfloxin, which inhibits RNA polymerase (Pol I) transcription and displaces nucleolin from the nucleolus, is a highly interesting test case. The design of the fluoroquinolone QQ58 (REF. 103 ) was based on the principle that norfloxacin and A-62176 inhibited gyrase and topoisomerase II by interacting with the enzyme-duplex DNA complex, and this scaffold was amenable to G-quadruplex interaction by extending the tetracyclic nucleus to a larger and approximately planar system that would interact more favourably with the tetrad in the G-quadruplex than with duplex DNA. Cylene Pharmaceuticals then optimized the planar, presumably G-tetrad-interacting moiety and identified groove-binding arms that would both prevent topoisomerase poisoning and increase selectivity between different G-quadruplexes. b | Diagram showing the proposed mechanism of action of quarfloxin specifically involving the MYC G-quadruplex 40, 102 . The other target proteins of nucleolin are mentioned in the main text. Quarfloxin is preferentially concentrated in the nucleolus. Binding of quarfloxin to the nontemplate G-quadruplexes in the recombinant DNA displaces nucleolin, which is relocated to the nucleoplasm, where it has been shown to bind to the MYC G-quadruplex to inhibit MYC expression 76 . RNA Pol I, RNA polymerase I. 
Quarfloxin, a first-in-class G-quadruplexinteracting drug. Quarfloxin (also known as CX-3543 or itarnafloxin), is a first-inclass G-quadruplex-interacting compound that had reached Phase II clinical trials for the treatment of neuroendocrine/carcinoid tumours (ClinicalTrials.gov identifier: NCT00780663) 102 . Quarfloxin was originally derived from a group of fluoroquinolones that were shown to have dual topoisomerase II and G-quadruplex interactions 103 and was successfully optimized by Cylene Pharmaceuticals to eliminate topoisomerase II activity and maximize selectivity for G-quadruplexes (FIG. 5a) . Quarfloxin has higher selectivity than TMPyP4 for allparallel G-quadruplex structures, including those from MYC, VEGF and T30695 promoters, in contrast to other alternatively folded structures 104 . Unexpectedly, quarfloxin was found to concentrate in the nucleolus and selectively inhibit Pol I transcription 102 . The inhibition of Pol I has been shown to be due to the disruption of the G-quadruplex-nucleolin complexes by quarfloxin, which in turn leads to cellular redistribution of nucleolin into the nucleoplasm. Examination of putative G-quadruplex-forming sequences in the non-template strand of recombinant DNA demonstrates a mixture of three parallel, two antiparallel and nine mixed (parallel and antiparallel) G-quadruplexes. Nucleolin and quarfloxin were both shown to bind to most of these G-quadruplexes, and quarfloxin was shown to disrupt all but one of these nucleolin-DNA complexes 102 . This effect was confirmed in cells by ChIP and immunofluorescence analyses, with the latter demonstrating that quarfloxin redistributed nucleolin within the cell (FIG. 5b) . The immediate consequence of the disruption of nucleolin ribosomal RNA G-quadruplex interaction by quarfloxin is selective inhibition of elongation of Pol I-driven transcription. The relocalization of nucleolin to the nucleoplasm is a common response to cellular stress, which results in selective apoptosis through various different pathways [105] [106] [107] [108] [109] [110] [111] . Intriguingly, it has recently been shown that nucleolin has high selectivity for the MYC G-quadruplex, where it inhibits MYC transcription (see before) 40 . Although quarfloxin did not inhibit MYC gene expression after a period of 2 hours in A549 cells 102 , it had previously been shown to inhibit MYC mRNA expression by 85% in HCT-116 tumours that were isolated from mice after treatment with quarfloxin 104 . FIGURE 5b summarizes the current understanding of the mechanism of action of quarfloxin.
Future directions
Since the cellular proof-of-concept study that demonstrated small-molecule modulation of MYC expression in 2002, there has been considerable progress in our understanding of G-quadruplex structures in gene promoter regions as a potential new class of drug targets. However, from a drug discovery perspective, we are still in the very early days, and progress is severely hampered by the lack of structural information on smallmolecule-G-quadruplex complexes in gene promoter elements.
Apart from the native structures listed in BOX 3,  there is just one structure for a ligand-promoter G-quadruplex complex that is currently available in the Protein Data Bank, that of an MYC G-quadruplexTMPyP4 complex, which is derived from a mutant sequence that forms a folding pattern with similarities to that of KIT1 (REF. 22 ). However, there are now several structures that are derived mostly from crystallographic analyses of telomeric G-quadruplex ligand complexes [112] [113] [114] . It is hoped that the therapeutic potential shown by quarfloxin and other agents in earlier stages of development will encourage more chemists and biologists to undertake structural studies in this area. BOX 5 summarizes some of the advantages and challenges of gene promoter G-quadruplexes as therapeutic targets compared to enzymes, proteins or telomeric G-quadruplexes in oncology. The promise and potential is high: the challenges are considerable but surmountable.
Although the putative G-quadruplexforming sequences present an opportunity for a range of drug targets, they also represent a potential problem of drug selectivity. Further progress on the development of small molecules with specificity and high affinity for a particular gene promoter G-quadruplex could come from either the screening of large compound libraries or the use of structure-based design methods, including in silico screening against virtual compound libraries.
The G-quadruplex field could thus be viewed as analogous to targeting a particular human kinase. Formerly, this was widely believed to be an unrealistic challenge in view of the similarity of ATP binding sites in many kinases; however, it is now clear that this challenge can be met. This has been illustrated by approved drugs such as gefitinib (Iressa; AstraZeneca), which targets a mutated tyrosine kinase domain in EGFR 115 , and by targeting the mutated serine-threonine BRAF kinase in patients with melanoma using the kinase inhibitor PLX4032 (REF. 116 ). Conversely, the clinical successes of some relatively non-selective kinase inhibitors, not least of which is imatinib itself, suggest that a measure of broad-spectrum activity against several oncogenic promoter G-quadruplexes may be therapeutically useful.
Studies with MYC suggest that it is the targeting of protein-G-quadruplex complexes (for example, the NM23H2-MYC-G-quadruplex) that leads to the biological consequences; therefore, identification of the specific proteins that bind to these sequences to modulate gene expression will be vital for understanding how the drugs exert their biological effects. This is analogous to the telomeric G-quadruplex studies, as well as DNA complexes with topoisomerases I and II.
Although quarfloxin did not proceed past Phase II trials because of bioavailability issues, the toxicity profile was very encouraging and suggests that medicinal chemistry optimization in the future could result in a compound with more favourable pharmacological properties. Quarfloxin was well tolerated by patients, and neither genotoxicity nor major organ toxicities were experienced. Furthermore, objective responses were observed during the Phase I clinical trials 143 .
Box 5 | Comparison of different G-quadruplex-targeted anticancer strategies
The potential advantages and challenges of targeting gene promoter G-quadruplexes compared to protein, enzyme or telomeric G-quadruplex targets are summarized below.
Gene promoter G-quadruplex targets

Advantages:
• Can target genes regardless of the druggability of the gene product
• Lower likelihood of point mutations and resistance
• Fewer copies of target, hence low concentration of inhibitor needed; this contrasts with the larger numbers (that is higher concentrations) of an overexpressing oncogenic protein or enzyme
• Potential of unique sequence and three-dimensional structure for a given G-quadruplex -drug selectivity may be achievable by design
• A number of relevant oncogenes and kinases are established as clinically validated targets in cancer: for example, KIT and BRAF
• Downregulation of expression of a target oncogene may be more important for tumour progression in a particular tumour type than telomerase (for example, BRAF in some melanomas); therefore, oncogene expression may be a more critical target for selective cell killing
• High-throughput functional assays are available for many oncogenes and kinase targets, and are readily applicable to screening effects of promoter G-quadruplex targeting Challenges:
• High affinity and selectivity needed, yet even the potency of state-of-the-art G-quadruplex ligands is considerably lower than that of typical enzyme inhibitors (often in the nanomolar range)
• Folding and structure can alter following ligand binding
• As yet restricted diversity in available small-molecule inhibitors
• Three-dimensional structures of very few promoter G-quadruplexes have been determined to date
Protein targets
Advantages:
• Straightforward if target has a well-defined active site
• Large specialized compound libraries are available (for example, for kinases)
• Structural data are available on many existing targets Challenges:
• Challenging if it involves protein-protein recognition Last, the overwhelming emphasis has been on studies targeting G-quadruplexes in gene promoter regions. As the i-motif appears to exist under negative supercoiling conditions, this represents a second opportunity for involvement in the control of gene expression and drug targeting.
